Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial.

Kantarjian H, Deininger M, Apperley JF, Arthur CK, Chuah C, Hochhaus A, de Lavallade H, Lipton JH, Lomaia E, McCloskey J, Maness L, Mauro M, Moiraghi B, Pavlovsky C, Rosti G, Rousselot P, Chao B, Vorog A, Reddick LE, Patel N, Hennessy M, Yeh T, Cortes J

Open source

DOI: 10.1038/s41375-026-03009-x
Published: 2026 Sep
Container: Leukemia
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41375-026-03009-x,
  title = {Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial.},
  author = {Kantarjian H and Deininger M and Apperley JF and Arthur CK and Chuah C and Hochhaus A and de Lavallade H and Lipton JH and Lomaia E and McCloskey J and Maness L and Mauro M and Moiraghi B and Pavlovsky C and Rosti G and Rousselot P and Chao B and Vorog A and Reddick LE and Patel N and Hennessy M and Yeh T and Cortes J},
  year = {2026},
  journal = {Leukemia},
  doi = {10.1038/s41375-026-03009-x},
  url = {https://doi.org/10.1038/s41375-026-03009-x}
}

RIS

TY  - JOUR
TI  - Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial.
AU  - Kantarjian H
AU  - Deininger M
AU  - Apperley JF
AU  - Arthur CK
AU  - Chuah C
AU  - Hochhaus A
AU  - de Lavallade H
AU  - Lipton JH
AU  - Lomaia E
AU  - McCloskey J
AU  - Maness L
AU  - Mauro M
AU  - Moiraghi B
AU  - Pavlovsky C
AU  - Rosti G
AU  - Rousselot P
AU  - Chao B
AU  - Vorog A
AU  - Reddick LE
AU  - Patel N
AU  - Hennessy M
AU  - Yeh T
AU  - Cortes J
PY  - 2026
JO  - Leukemia
DO  - 10.1038/s41375-026-03009-x
UR  - https://doi.org/10.1038/s41375-026-03009-x
ER  -

APA

H, K., M, D., JF, A., CK, A., C, C., A, H., H, D. L., JH, L., E, L., J, M., L, M., M, M., B, M., C, P., G, R., P, R., B, C., A, V., LE, R., N, P., M, H., T, Y., & J, C. (2026). Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial.. Leukemia. https://doi.org/10.1038/s41375-026-03009-x

Source records

pubmed · retrieved 2026-09-26T16:44:36.044Z